 Martin McCarter
Concepts (754)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Melanoma | 44 | 2023 | 649 | 6.820 |
Why?
| | Esophageal Neoplasms | 25 | 2023 | 273 | 5.360 |
Why?
| | Skin Neoplasms | 29 | 2023 | 760 | 3.720 |
Why?
| | Esophagectomy | 18 | 2023 | 111 | 3.360 |
Why?
| | Adenocarcinoma | 23 | 2023 | 797 | 3.040 |
Why?
| | Sentinel Lymph Node Biopsy | 21 | 2022 | 98 | 2.530 |
Why?
| | Myeloid-Derived Suppressor Cells | 4 | 2023 | 54 | 2.500 |
Why?
| | Gastrointestinal Stromal Tumors | 10 | 2022 | 43 | 2.380 |
Why?
| | Neoadjuvant Therapy | 12 | 2023 | 301 | 1.850 |
Why?
| | Sentinel Lymph Node | 9 | 2022 | 38 | 1.830 |
Why?
| | Dendritic Cells | 13 | 2019 | 438 | 1.800 |
Why?
| | T-Lymphocytes, Regulatory | 11 | 2022 | 340 | 1.790 |
Why?
| | Pancreatic Neoplasms | 14 | 2021 | 721 | 1.770 |
Why?
| | Neoplasm Recurrence, Local | 18 | 2019 | 862 | 1.670 |
Why?
| | Tumor Escape | 4 | 2017 | 35 | 1.320 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 8 | 2023 | 1360 | 1.280 |
Why?
| | Lymphatic Metastasis | 18 | 2023 | 276 | 1.280 |
Why?
| | Hyperthermia, Induced | 4 | 2020 | 65 | 1.270 |
Why?
| | Neoplasm Staging | 29 | 2023 | 1177 | 1.210 |
Why?
| | Middle Aged | 90 | 2022 | 27078 | 1.120 |
Why?
| | Hyperglycemia | 3 | 2020 | 295 | 1.110 |
Why?
| | Humans | 186 | 2024 | 115859 | 1.100 |
Why?
| | Aged | 76 | 2021 | 19292 | 1.090 |
Why?
| | HIV-1 | 16 | 2022 | 771 | 1.070 |
Why?
| | Retrospective Studies | 49 | 2023 | 12615 | 1.060 |
Why?
| | Lymph Nodes | 14 | 2023 | 423 | 1.040 |
Why?
| | Neoplasms | 10 | 2024 | 2114 | 1.040 |
Why?
| | HIV Infections | 20 | 2022 | 2471 | 1.020 |
Why?
| | CD4-Positive T-Lymphocytes | 13 | 2021 | 967 | 1.010 |
Why?
| | Postoperative Complications | 19 | 2023 | 2164 | 1.000 |
Why?
| | Rectal Neoplasms | 7 | 2023 | 122 | 1.000 |
Why?
| | Intestinal Mucosa | 10 | 2021 | 528 | 0.940 |
Why?
| | Peritoneal Neoplasms | 3 | 2020 | 54 | 0.900 |
Why?
| | Laparoscopy | 7 | 2023 | 400 | 0.850 |
Why?
| | Pancreaticoduodenectomy | 7 | 2021 | 130 | 0.840 |
Why?
| | Lymph Node Excision | 8 | 2022 | 141 | 0.840 |
Why?
| | Male | 101 | 2022 | 56103 | 0.840 |
Why?
| | Cytoreduction Surgical Procedures | 4 | 2020 | 40 | 0.830 |
Why?
| | Tretinoin | 3 | 2023 | 123 | 0.820 |
Why?
| | Female | 110 | 2022 | 60070 | 0.820 |
Why?
| | Neoplasms, Second Primary | 1 | 2023 | 91 | 0.800 |
Why?
| | Lymphocyte Activation | 11 | 2018 | 1056 | 0.780 |
Why?
| | Sarcoma | 5 | 2022 | 137 | 0.780 |
Why?
| | Stomach Neoplasms | 2 | 2019 | 66 | 0.780 |
Why?
| | Radiosurgery | 4 | 2020 | 298 | 0.760 |
Why?
| | Pelvic Exenteration | 4 | 2019 | 11 | 0.750 |
Why?
| | Proto-Oncogene Proteins c-kit | 5 | 2022 | 63 | 0.750 |
Why?
| | T-Lymphocytes | 6 | 2018 | 1758 | 0.750 |
Why?
| | Survival Analysis | 16 | 2022 | 1218 | 0.710 |
Why?
| | Splenectomy | 1 | 2020 | 54 | 0.700 |
Why?
| | Adult | 60 | 2020 | 30814 | 0.690 |
Why?
| | Prognosis | 22 | 2022 | 3344 | 0.690 |
Why?
| | Gastrointestinal Microbiome | 8 | 2021 | 504 | 0.680 |
Why?
| | Piperazines | 5 | 2014 | 314 | 0.680 |
Why?
| | Pancreatic Cyst | 2 | 2017 | 47 | 0.680 |
Why?
| | Ipilimumab | 2 | 2019 | 28 | 0.680 |
Why?
| | Spleen | 6 | 2017 | 492 | 0.670 |
Why?
| | Anastomotic Leak | 3 | 2023 | 28 | 0.660 |
Why?
| | Myeloid Cells | 3 | 2020 | 127 | 0.660 |
Why?
| | Pyrimidines | 5 | 2014 | 376 | 0.650 |
Why?
| | Radiotherapy, Intensity-Modulated | 2 | 2018 | 123 | 0.640 |
Why?
| | Granulocytes | 2 | 2017 | 78 | 0.640 |
Why?
| | Colorectal Neoplasms | 5 | 2017 | 617 | 0.620 |
Why?
| | Leukocytes, Mononuclear | 5 | 2021 | 503 | 0.610 |
Why?
| | Aged, 80 and over | 27 | 2020 | 6434 | 0.610 |
Why?
| | Monocytes | 2 | 2020 | 504 | 0.600 |
Why?
| | Appendiceal Neoplasms | 1 | 2017 | 14 | 0.600 |
Why?
| | Survival Rate | 17 | 2021 | 1649 | 0.590 |
Why?
| | Gastric Outlet Obstruction | 1 | 2017 | 7 | 0.570 |
Why?
| | Pylorus | 1 | 2017 | 11 | 0.570 |
Why?
| | CD8-Positive T-Lymphocytes | 5 | 2023 | 688 | 0.570 |
Why?
| | Head and Neck Neoplasms | 5 | 2019 | 425 | 0.560 |
Why?
| | Soft Tissue Neoplasms | 3 | 2022 | 90 | 0.550 |
Why?
| | Antineoplastic Agents, Immunological | 1 | 2018 | 153 | 0.550 |
Why?
| | Neuromuscular Agents | 1 | 2017 | 30 | 0.550 |
Why?
| | Botulinum Toxins, Type A | 1 | 2017 | 40 | 0.540 |
Why?
| | Leucovorin | 2 | 2019 | 42 | 0.540 |
Why?
| | Antineoplastic Agents | 8 | 2021 | 1891 | 0.510 |
Why?
| | Combined Modality Therapy | 13 | 2023 | 1127 | 0.490 |
Why?
| | Vitamin B Complex | 1 | 2014 | 37 | 0.480 |
Why?
| | Chemoradiotherapy | 5 | 2023 | 187 | 0.480 |
Why?
| | Immune Tolerance | 4 | 2016 | 331 | 0.480 |
Why?
| | Salvage Therapy | 2 | 2014 | 128 | 0.470 |
Why?
| | Lymphocytes | 3 | 2021 | 342 | 0.470 |
Why?
| | Treatment Outcome | 24 | 2023 | 9163 | 0.470 |
Why?
| | Minimally Invasive Surgical Procedures | 6 | 2023 | 154 | 0.460 |
Why?
| | Pelvis | 1 | 2014 | 92 | 0.460 |
Why?
| | Pancreatectomy | 4 | 2021 | 168 | 0.440 |
Why?
| | Ear, External | 1 | 2013 | 23 | 0.440 |
Why?
| | Ischemic Preconditioning | 2 | 2023 | 28 | 0.440 |
Why?
| | Mohs Surgery | 1 | 2013 | 24 | 0.440 |
Why?
| | Mutation | 8 | 2022 | 3371 | 0.430 |
Why?
| | Palliative Care | 1 | 2019 | 642 | 0.430 |
Why?
| | Follow-Up Studies | 15 | 2019 | 4443 | 0.430 |
Why?
| | Melanoma, Experimental | 3 | 2022 | 118 | 0.430 |
Why?
| | T-Lymphocytes, Helper-Inducer | 4 | 2017 | 129 | 0.420 |
Why?
| | Liver Neoplasms | 5 | 2016 | 521 | 0.420 |
Why?
| | Biopsy | 3 | 2023 | 1056 | 0.420 |
Why?
| | Esophagogastric Junction | 3 | 2021 | 42 | 0.400 |
Why?
| | Carcinoma, Squamous Cell | 2 | 2014 | 577 | 0.400 |
Why?
| | Hematologic Diseases | 1 | 2012 | 57 | 0.400 |
Why?
| | Suppressor Factors, Immunologic | 1 | 2011 | 4 | 0.400 |
Why?
| | Surgical Wound Infection | 1 | 2014 | 251 | 0.400 |
Why?
| | Receptors, CCR5 | 3 | 2021 | 54 | 0.390 |
Why?
| | Cytokines | 8 | 2021 | 1858 | 0.390 |
Why?
| | Colonic Neoplasms | 6 | 2012 | 222 | 0.390 |
Why?
| | Prospective Studies | 19 | 2023 | 6276 | 0.380 |
Why?
| | Up-Regulation | 4 | 2012 | 824 | 0.380 |
Why?
| | Induction Chemotherapy | 2 | 2021 | 56 | 0.380 |
Why?
| | Granzymes | 2 | 2021 | 40 | 0.360 |
Why?
| | Conversion to Open Surgery | 2 | 2020 | 13 | 0.360 |
Why?
| | Gastrointestinal Hemorrhage | 2 | 2022 | 102 | 0.360 |
Why?
| | Homosexuality, Male | 3 | 2021 | 170 | 0.350 |
Why?
| | Benzamides | 5 | 2014 | 169 | 0.350 |
Why?
| | Esophageal Achalasia | 2 | 2021 | 25 | 0.350 |
Why?
| | Retroperitoneal Neoplasms | 3 | 2021 | 22 | 0.340 |
Why?
| | Young Adult | 18 | 2019 | 10508 | 0.340 |
Why?
| | Medical Oncology | 4 | 2022 | 230 | 0.340 |
Why?
| | Mucous Membrane | 4 | 2023 | 108 | 0.340 |
Why?
| | Interferon-gamma | 6 | 2019 | 733 | 0.340 |
Why?
| | Wounds and Injuries | 4 | 2009 | 731 | 0.330 |
Why?
| | Membrane Glycoproteins | 3 | 2015 | 433 | 0.330 |
Why?
| | Single Photon Emission Computed Tomography Computed Tomography | 2 | 2019 | 11 | 0.330 |
Why?
| | Cell Differentiation | 5 | 2016 | 1709 | 0.320 |
Why?
| | Butyrates | 2 | 2021 | 53 | 0.320 |
Why?
| | Barrett Esophagus | 3 | 2020 | 147 | 0.320 |
Why?
| | Interleukin-15 | 2 | 2021 | 76 | 0.320 |
Why?
| | Killer Cells, Natural | 2 | 2023 | 381 | 0.320 |
Why?
| | Immunity, Mucosal | 3 | 2016 | 85 | 0.320 |
Why?
| | Blood Preservation | 2 | 2009 | 263 | 0.310 |
Why?
| | Chemotherapy, Adjuvant | 9 | 2023 | 334 | 0.310 |
Why?
| | Disease-Free Survival | 8 | 2019 | 621 | 0.300 |
Why?
| | Inflammation Mediators | 2 | 2018 | 480 | 0.300 |
Why?
| | Colon | 3 | 2021 | 234 | 0.290 |
Why?
| | Nomograms | 2 | 2019 | 42 | 0.290 |
Why?
| | Prostatic Neoplasms | 1 | 2014 | 927 | 0.290 |
Why?
| | Dysbiosis | 3 | 2021 | 146 | 0.290 |
Why?
| | Paraneoplastic Syndromes | 1 | 2007 | 13 | 0.290 |
Why?
| | Immunocompromised Host | 1 | 2008 | 197 | 0.280 |
Why?
| | Erythrocyte Transfusion | 1 | 2008 | 187 | 0.280 |
Why?
| | Cells, Cultured | 9 | 2021 | 3914 | 0.280 |
Why?
| | Population Surveillance | 2 | 2021 | 395 | 0.280 |
Why?
| | Splenic Neoplasms | 1 | 2006 | 2 | 0.270 |
Why?
| | Forkhead Transcription Factors | 1 | 2007 | 170 | 0.270 |
Why?
| | Lymphangioma | 1 | 2006 | 7 | 0.270 |
Why?
| | Pelvic Neoplasms | 3 | 2012 | 19 | 0.270 |
Why?
| | Th2 Cells | 2 | 2005 | 162 | 0.270 |
Why?
| | General Surgery | 1 | 2007 | 130 | 0.260 |
Why?
| | Receptors, Cell Surface | 2 | 2021 | 358 | 0.260 |
Why?
| | Carcinoma, Pancreatic Ductal | 2 | 2021 | 208 | 0.260 |
Why?
| | Neuroendocrine Tumors | 2 | 2017 | 83 | 0.260 |
Why?
| | Transplantation Immunology | 1 | 2005 | 31 | 0.260 |
Why?
| | Mentors | 1 | 2007 | 162 | 0.260 |
Why?
| | Immunity, Innate | 4 | 2021 | 735 | 0.260 |
Why?
| | Catheter Ablation | 4 | 2016 | 291 | 0.260 |
Why?
| | Macrophages, Peritoneal | 3 | 2005 | 93 | 0.260 |
Why?
| | Exome | 2 | 2017 | 206 | 0.260 |
Why?
| | Nevus, Epithelioid and Spindle Cell | 1 | 2005 | 7 | 0.260 |
Why?
| | B-Lymphocytes | 3 | 2017 | 771 | 0.250 |
Why?
| | Virus Replication | 5 | 2017 | 396 | 0.250 |
Why?
| | Microbiota | 3 | 2024 | 652 | 0.250 |
Why?
| | Radiation Injuries | 2 | 2021 | 128 | 0.250 |
Why?
| | Interleukin-10 | 3 | 2016 | 304 | 0.250 |
Why?
| | Culture Media, Conditioned | 4 | 2011 | 105 | 0.240 |
Why?
| | Signal Transduction | 9 | 2023 | 4527 | 0.240 |
Why?
| | Nevus, Pigmented | 1 | 2005 | 34 | 0.240 |
Why?
| | Adolescent | 15 | 2019 | 17935 | 0.240 |
Why?
| | Th1 Cells | 2 | 2019 | 125 | 0.240 |
Why?
| | Macrophage Activation | 1 | 2005 | 165 | 0.240 |
Why?
| | Lymphocytes, Tumor-Infiltrating | 3 | 2022 | 107 | 0.240 |
Why?
| | Erythrocytes | 1 | 2009 | 590 | 0.240 |
Why?
| | Feces | 4 | 2021 | 373 | 0.230 |
Why?
| | Anus Neoplasms | 2 | 2003 | 24 | 0.230 |
Why?
| | Lymphangiogenesis | 1 | 2004 | 24 | 0.230 |
Why?
| | Flow Cytometry | 6 | 2017 | 1060 | 0.230 |
Why?
| | Lymphocyte Count | 5 | 2017 | 133 | 0.230 |
Why?
| | Interferon-alpha | 3 | 2015 | 187 | 0.230 |
Why?
| | Ruminococcus | 2 | 2021 | 9 | 0.230 |
Why?
| | Education, Medical, Graduate | 1 | 2007 | 378 | 0.220 |
Why?
| | Enterobacteriaceae | 2 | 2017 | 33 | 0.220 |
Why?
| | Paget Disease, Extramammary | 1 | 2003 | 3 | 0.220 |
Why?
| | In Vitro Techniques | 5 | 2019 | 1044 | 0.220 |
Why?
| | Receptors, G-Protein-Coupled | 2 | 2022 | 193 | 0.220 |
Why?
| | Lymphoid Tissue | 3 | 2008 | 63 | 0.220 |
Why?
| | Neoplasm Metastasis | 2 | 2007 | 526 | 0.210 |
Why?
| | Lymphoscintigraphy | 2 | 2019 | 9 | 0.210 |
Why?
| | Lysophospholipids | 1 | 2023 | 65 | 0.210 |
Why?
| | Transforming Growth Factor beta | 4 | 2015 | 447 | 0.210 |
Why?
| | Specialties, Surgical | 1 | 2023 | 71 | 0.210 |
Why?
| | Biomarkers, Tumor | 4 | 2017 | 1045 | 0.210 |
Why?
| | Protein-Energy Malnutrition | 2 | 2003 | 7 | 0.210 |
Why?
| | Intestines | 2 | 2017 | 325 | 0.210 |
Why?
| | Salmonella typhimurium | 2 | 2021 | 161 | 0.210 |
Why?
| | Tomography, X-Ray Computed | 6 | 2016 | 2404 | 0.210 |
Why?
| | Cell Count | 2 | 2017 | 304 | 0.210 |
Why?
| | Time Factors | 9 | 2014 | 6182 | 0.210 |
Why?
| | Bacteria | 3 | 2018 | 730 | 0.210 |
Why?
| | Hepatectomy | 2 | 2016 | 137 | 0.210 |
Why?
| | Mice | 20 | 2022 | 15085 | 0.210 |
Why?
| | Tumor Microenvironment | 5 | 2024 | 424 | 0.200 |
Why?
| | Hematologic Neoplasms | 1 | 2024 | 135 | 0.200 |
Why?
| | Receptors, CXCR3 | 1 | 2022 | 15 | 0.200 |
Why?
| | Chemokine CXCL9 | 1 | 2022 | 22 | 0.200 |
Why?
| | Imatinib Mesylate | 5 | 2014 | 64 | 0.200 |
Why?
| | Cryosurgery | 2 | 2019 | 52 | 0.200 |
Why?
| | Critical Pathways | 1 | 2022 | 75 | 0.200 |
Why?
| | HIV Seropositivity | 1 | 2022 | 110 | 0.200 |
Why?
| | Esophagoscopy | 2 | 2020 | 183 | 0.200 |
Why?
| | Disease Progression | 2 | 2022 | 2423 | 0.200 |
Why?
| | Chemokine CXCL10 | 1 | 2022 | 36 | 0.200 |
Why?
| | Acinetobacter | 1 | 2021 | 13 | 0.190 |
Why?
| | T-Lymphocytes, Cytotoxic | 3 | 2022 | 156 | 0.190 |
Why?
| | Glucose | 3 | 2020 | 903 | 0.190 |
Why?
| | B7-H1 Antigen | 1 | 2023 | 138 | 0.190 |
Why?
| | Seminoma | 1 | 2021 | 17 | 0.190 |
Why?
| | ADAM10 Protein | 1 | 2021 | 27 | 0.190 |
Why?
| | Firmicutes | 1 | 2021 | 17 | 0.190 |
Why?
| | Anastomosis, Surgical | 2 | 2023 | 140 | 0.190 |
Why?
| | Gamma Rays | 1 | 2021 | 47 | 0.180 |
Why?
| | Interleukin-2 | 5 | 2022 | 416 | 0.180 |
Why?
| | Bacterial Translocation | 2 | 2019 | 36 | 0.180 |
Why?
| | Delivery of Health Care | 2 | 2021 | 847 | 0.180 |
Why?
| | Diarrhea | 3 | 2008 | 173 | 0.180 |
Why?
| | Amyloid Precursor Protein Secretases | 1 | 2021 | 72 | 0.180 |
Why?
| | Group II Phospholipases A2 | 1 | 2020 | 19 | 0.180 |
Why?
| | Receptors, CCR | 1 | 2020 | 7 | 0.180 |
Why?
| | Carcinoembryonic Antigen | 2 | 2022 | 37 | 0.180 |
Why?
| | Neoplasms, Germ Cell and Embryonal | 1 | 2021 | 60 | 0.180 |
Why?
| | Interleukins | 2 | 2019 | 237 | 0.180 |
Why?
| | Platelet Count | 1 | 2020 | 83 | 0.180 |
Why?
| | Cell Proliferation | 6 | 2021 | 2196 | 0.180 |
Why?
| | Risk Factors | 11 | 2019 | 8715 | 0.170 |
Why?
| | Basophils | 1 | 2020 | 64 | 0.170 |
Why?
| | Lymphocyte Subsets | 1 | 2020 | 78 | 0.170 |
Why?
| | Surgeons | 1 | 2023 | 238 | 0.170 |
Why?
| | Decision Making | 2 | 2019 | 790 | 0.170 |
Why?
| | Histone Deacetylase Inhibitors | 1 | 2021 | 198 | 0.170 |
Why?
| | Patient Care Planning | 2 | 2016 | 142 | 0.170 |
Why?
| | Scalp | 1 | 2019 | 29 | 0.170 |
Why?
| | Gastric Bypass | 1 | 2021 | 94 | 0.170 |
Why?
| | Dacarbazine | 4 | 2012 | 100 | 0.170 |
Why?
| | Epithelial-Mesenchymal Transition | 1 | 2021 | 168 | 0.170 |
Why?
| | Apoptosis | 5 | 2021 | 2377 | 0.170 |
Why?
| | Immunophenotyping | 2 | 2017 | 273 | 0.170 |
Why?
| | Th17 Cells | 1 | 2019 | 58 | 0.170 |
Why?
| | Sclerosing Solutions | 1 | 2019 | 9 | 0.170 |
Why?
| | Argon Plasma Coagulation | 1 | 2019 | 4 | 0.170 |
Why?
| | Leukocyte Count | 1 | 2020 | 295 | 0.170 |
Why?
| | Germ-Free Life | 1 | 2019 | 30 | 0.170 |
Why?
| | Receptor, Platelet-Derived Growth Factor alpha | 2 | 2022 | 41 | 0.170 |
Why?
| | Preoperative Care | 2 | 2018 | 318 | 0.170 |
Why?
| | Sclerotherapy | 1 | 2019 | 19 | 0.170 |
Why?
| | CD4 Antigens | 2 | 2011 | 124 | 0.170 |
Why?
| | Haploinsufficiency | 1 | 2019 | 43 | 0.170 |
Why?
| | Nutritional Support | 1 | 2019 | 27 | 0.170 |
Why?
| | Self Expandable Metallic Stents | 1 | 2019 | 14 | 0.160 |
Why?
| | Abdominal Neoplasms | 2 | 2010 | 26 | 0.160 |
Why?
| | Survivors | 2 | 2015 | 404 | 0.160 |
Why?
| | Immunotherapy | 4 | 2024 | 481 | 0.160 |
Why?
| | Mastocytosis | 1 | 2019 | 12 | 0.160 |
Why?
| | Photochemotherapy | 1 | 2019 | 29 | 0.160 |
Why?
| | Intestinal Perforation | 1 | 2019 | 38 | 0.160 |
Why?
| | Animals | 23 | 2022 | 32158 | 0.160 |
Why?
| | Postoperative Period | 1 | 2020 | 292 | 0.160 |
Why?
| | CTLA-4 Antigen | 1 | 2019 | 78 | 0.160 |
Why?
| | Gram-Positive Bacteria | 1 | 2019 | 46 | 0.160 |
Why?
| | Tissue and Organ Procurement | 1 | 2022 | 243 | 0.160 |
Why?
| | HLA-DR Antigens | 2 | 2011 | 220 | 0.160 |
Why?
| | Intestinal Obstruction | 1 | 2019 | 41 | 0.160 |
Why?
| | Gram-Negative Bacteria | 1 | 2019 | 67 | 0.160 |
Why?
| | Skin Pigmentation | 1 | 2019 | 39 | 0.160 |
Why?
| | Dilatation | 1 | 2019 | 59 | 0.160 |
Why?
| | Environmental Restoration and Remediation | 1 | 2018 | 8 | 0.160 |
Why?
| | Esophagus | 1 | 2020 | 226 | 0.160 |
Why?
| | Fibrosis | 1 | 2021 | 458 | 0.160 |
Why?
| | Brachytherapy | 1 | 2019 | 104 | 0.160 |
Why?
| | Hospitals | 2 | 2021 | 585 | 0.150 |
Why?
| | Germ-Line Mutation | 1 | 2019 | 134 | 0.150 |
Why?
| | Venous Thromboembolism | 2 | 2012 | 234 | 0.150 |
Why?
| | Septins | 1 | 2018 | 40 | 0.150 |
Why?
| | Endoscopic Mucosal Resection | 1 | 2018 | 22 | 0.150 |
Why?
| | Oncogene Proteins v-abl | 1 | 2017 | 4 | 0.150 |
Why?
| | Liver | 4 | 2016 | 1693 | 0.150 |
Why?
| | Laser Therapy | 1 | 2019 | 99 | 0.150 |
Why?
| | Cell Movement | 4 | 2022 | 867 | 0.150 |
Why?
| | HIV | 1 | 2019 | 209 | 0.150 |
Why?
| | Enteral Nutrition | 2 | 2010 | 157 | 0.150 |
Why?
| | Dasatinib | 1 | 2017 | 45 | 0.150 |
Why?
| | Down-Regulation | 1 | 2020 | 605 | 0.150 |
Why?
| | Deglutition Disorders | 1 | 2019 | 119 | 0.150 |
Why?
| | Viral Tropism | 1 | 2017 | 24 | 0.150 |
Why?
| | Food, Formulated | 1 | 1997 | 17 | 0.150 |
Why?
| | Carcinoid Tumor | 1 | 2017 | 25 | 0.150 |
Why?
| | Protein Kinase Inhibitors | 3 | 2018 | 789 | 0.150 |
Why?
| | Neurofibromin 1 | 1 | 2017 | 22 | 0.150 |
Why?
| | Common Bile Duct Neoplasms | 1 | 2017 | 23 | 0.150 |
Why?
| | Ampulla of Vater | 1 | 2017 | 28 | 0.150 |
Why?
| | Fatty Acids, Omega-3 | 1 | 1998 | 125 | 0.140 |
Why?
| | src-Family Kinases | 1 | 2017 | 87 | 0.140 |
Why?
| | Disease Management | 1 | 2021 | 563 | 0.140 |
Why?
| | Endoscopy, Gastrointestinal | 1 | 2019 | 202 | 0.140 |
Why?
| | Arginine | 1 | 1998 | 242 | 0.140 |
Why?
| | RNA Splicing Factors | 1 | 2017 | 50 | 0.140 |
Why?
| | Gastric Emptying | 1 | 2017 | 40 | 0.140 |
Why?
| | Thrombelastography | 1 | 2018 | 179 | 0.140 |
Why?
| | Perioperative Care | 1 | 2018 | 127 | 0.140 |
Why?
| | Oncogene Proteins, Fusion | 1 | 2018 | 178 | 0.140 |
Why?
| | Proto-Oncogene Proteins B-raf | 1 | 2018 | 190 | 0.140 |
Why?
| | Hospitals, High-Volume | 1 | 2016 | 39 | 0.140 |
Why?
| | Gastrectomy | 1 | 2017 | 83 | 0.140 |
Why?
| | Enzyme Inhibitors | 1 | 2020 | 758 | 0.140 |
Why?
| | Nutritional Status | 1 | 2019 | 287 | 0.140 |
Why?
| | Cancer Care Facilities | 1 | 2016 | 30 | 0.140 |
Why?
| | Immunologic Memory | 2 | 2016 | 312 | 0.140 |
Why?
| | Digestive System Neoplasms | 1 | 2016 | 7 | 0.140 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2002 | 1217 | 0.140 |
Why?
| | Mortality | 1 | 2018 | 290 | 0.140 |
Why?
| | Digestive System Surgical Procedures | 1 | 1997 | 89 | 0.140 |
Why?
| | Genital Neoplasms, Female | 1 | 2017 | 73 | 0.140 |
Why?
| | Antigen Presentation | 1 | 2017 | 189 | 0.140 |
Why?
| | Genes, erbB-1 | 1 | 2016 | 18 | 0.140 |
Why?
| | Polysaccharides, Bacterial | 1 | 2016 | 65 | 0.140 |
Why?
| | Bystander Effect | 1 | 2016 | 15 | 0.140 |
Why?
| | Guidelines as Topic | 1 | 2018 | 247 | 0.130 |
Why?
| | Lymphocyte Depletion | 3 | 2013 | 115 | 0.130 |
Why?
| | Germinal Center | 1 | 2016 | 46 | 0.130 |
Why?
| | Exons | 3 | 2019 | 303 | 0.130 |
Why?
| | Neoplasms, Cystic, Mucinous, and Serous | 1 | 2016 | 25 | 0.130 |
Why?
| | T-Lymphocyte Subsets | 2 | 2024 | 383 | 0.130 |
Why?
| | Proto-Oncogene Proteins c-bcl-2 | 2 | 2021 | 213 | 0.130 |
Why?
| | United States | 11 | 2023 | 12319 | 0.130 |
Why?
| | Indoleamine-Pyrrole 2,3,-Dioxygenase | 2 | 2015 | 44 | 0.130 |
Why?
| | Morbidity | 3 | 2023 | 278 | 0.130 |
Why?
| | Postoperative Care | 1 | 1997 | 222 | 0.130 |
Why?
| | Tomography, Emission-Computed, Single-Photon | 1 | 2016 | 101 | 0.130 |
Why?
| | Cystadenoma, Mucinous | 1 | 2015 | 13 | 0.130 |
Why?
| | Adenoma | 1 | 2017 | 187 | 0.130 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 2 | 2008 | 796 | 0.130 |
Why?
| | Cystadenocarcinoma, Mucinous | 1 | 2015 | 14 | 0.130 |
Why?
| | Xenograft Model Antitumor Assays | 4 | 2021 | 703 | 0.130 |
Why?
| | Phosphoproteins | 1 | 2017 | 302 | 0.130 |
Why?
| | Simian Acquired Immunodeficiency Syndrome | 1 | 2015 | 69 | 0.130 |
Why?
| | Tumor Necrosis Factor-alpha | 4 | 2018 | 1137 | 0.120 |
Why?
| | Quality of Life | 2 | 2019 | 2390 | 0.120 |
Why?
| | Ileus | 1 | 2014 | 10 | 0.120 |
Why?
| | Carcinoma, Hepatocellular | 1 | 2016 | 224 | 0.120 |
Why?
| | Viral Load | 5 | 2018 | 406 | 0.120 |
Why?
| | Receptors, Ghrelin | 1 | 2014 | 7 | 0.120 |
Why?
| | Membrane Proteins | 1 | 2021 | 1033 | 0.120 |
Why?
| | Ethanol | 1 | 2019 | 549 | 0.120 |
Why?
| | Risk Assessment | 3 | 2019 | 2992 | 0.120 |
Why?
| | Vinblastine | 2 | 2012 | 61 | 0.120 |
Why?
| | Endosonography | 1 | 2016 | 140 | 0.120 |
Why?
| | Dietary Supplements | 1 | 1998 | 460 | 0.120 |
Why?
| | Drug Resistance, Neoplasm | 3 | 2016 | 638 | 0.120 |
Why?
| | Tumor Cells, Cultured | 4 | 2021 | 850 | 0.120 |
Why?
| | Gastrointestinal Agents | 1 | 2014 | 60 | 0.120 |
Why?
| | Lung Neoplasms | 2 | 2017 | 2206 | 0.120 |
Why?
| | Pilot Projects | 1 | 2018 | 1379 | 0.120 |
Why?
| | Fluorouracil | 2 | 2019 | 151 | 0.110 |
Why?
| | Gastrointestinal Tract | 1 | 2016 | 169 | 0.110 |
Why?
| | Blood Cell Count | 1 | 2013 | 52 | 0.110 |
Why?
| | Tumor Burden | 4 | 2022 | 261 | 0.110 |
Why?
| | RNA, Viral | 3 | 2013 | 564 | 0.110 |
Why?
| | Colectomy | 3 | 2008 | 87 | 0.110 |
Why?
| | Registries | 1 | 2021 | 1772 | 0.110 |
Why?
| | Databases, Factual | 4 | 2019 | 1137 | 0.110 |
Why?
| | Lipopolysaccharide Receptors | 1 | 2013 | 85 | 0.110 |
Why?
| | Cisplatin | 2 | 2012 | 263 | 0.110 |
Why?
| | Anti-Inflammatory Agents | 1 | 2016 | 447 | 0.110 |
Why?
| | Gastrointestinal Neoplasms | 1 | 2013 | 59 | 0.110 |
Why?
| | Stomach | 2 | 2023 | 101 | 0.110 |
Why?
| | HIV Antibodies | 1 | 2013 | 49 | 0.110 |
Why?
| | Genetic Predisposition to Disease | 2 | 2019 | 2201 | 0.110 |
Why?
| | Oligopeptides | 1 | 2014 | 248 | 0.110 |
Why?
| | Side-Population Cells | 1 | 2012 | 9 | 0.100 |
Why?
| | Hospital Mortality | 2 | 2016 | 779 | 0.100 |
Why?
| | Ablation Techniques | 1 | 2012 | 29 | 0.100 |
Why?
| | Chi-Square Distribution | 3 | 2014 | 501 | 0.100 |
Why?
| | Biomarkers | 2 | 2020 | 3474 | 0.100 |
Why?
| | Palatine Tonsil | 3 | 2017 | 30 | 0.100 |
Why?
| | Tertiary Care Centers | 1 | 2013 | 127 | 0.100 |
Why?
| | Biological Therapy | 1 | 2012 | 26 | 0.100 |
Why?
| | Efficiency, Organizational | 1 | 2013 | 126 | 0.100 |
Why?
| | Elective Surgical Procedures | 1 | 2013 | 154 | 0.100 |
Why?
| | Macrophages | 2 | 2001 | 1282 | 0.100 |
Why?
| | Patient Care Team | 1 | 2016 | 522 | 0.100 |
Why?
| | Time-to-Treatment | 1 | 2013 | 147 | 0.100 |
Why?
| | Escherichia coli Infections | 1 | 2012 | 102 | 0.100 |
Why?
| | RNA, Ribosomal, 16S | 3 | 2019 | 489 | 0.100 |
Why?
| | ADP-ribosyl Cyclase 1 | 1 | 2011 | 36 | 0.100 |
Why?
| | Aldehyde Dehydrogenase | 1 | 2012 | 129 | 0.100 |
Why?
| | Predictive Value of Tests | 5 | 2018 | 1813 | 0.100 |
Why?
| | Proctocolectomy, Restorative | 1 | 2011 | 19 | 0.100 |
Why?
| | Colonic Pouches | 1 | 2011 | 14 | 0.100 |
Why?
| | Toll-Like Receptors | 2 | 2018 | 166 | 0.100 |
Why?
| | Intestinal Neoplasms | 1 | 2011 | 24 | 0.100 |
Why?
| | Mice, Inbred C57BL | 5 | 2021 | 4779 | 0.090 |
Why?
| | Ligands | 2 | 2023 | 570 | 0.090 |
Why?
| | Referral and Consultation | 1 | 2016 | 647 | 0.090 |
Why?
| | Antibodies, Neutralizing | 1 | 2013 | 223 | 0.090 |
Why?
| | Extremities | 2 | 2022 | 113 | 0.090 |
Why?
| | Antigens, Neoplasm | 2 | 2009 | 224 | 0.090 |
Why?
| | Multivariate Analysis | 4 | 2016 | 1443 | 0.090 |
Why?
| | Antigens, CD | 2 | 2015 | 443 | 0.090 |
Why?
| | Endocytosis | 1 | 2011 | 152 | 0.090 |
Why?
| | Cell Separation | 2 | 2010 | 293 | 0.090 |
Why?
| | Toll-Like Receptor 8 | 1 | 2010 | 5 | 0.090 |
Why?
| | Heparin | 1 | 2012 | 227 | 0.090 |
Why?
| | Interleukin-23 | 1 | 2010 | 15 | 0.090 |
Why?
| | Cohort Studies | 5 | 2019 | 4960 | 0.090 |
Why?
| | Cell Transformation, Neoplastic | 1 | 2012 | 312 | 0.090 |
Why?
| | Gastric Fistula | 1 | 2010 | 4 | 0.090 |
Why?
| | Toll-Like Receptor 7 | 1 | 2010 | 35 | 0.090 |
Why?
| | Vascular Surgical Procedures | 1 | 2013 | 262 | 0.090 |
Why?
| | Escherichia coli | 1 | 2014 | 730 | 0.090 |
Why?
| | Cutaneous Fistula | 1 | 2010 | 13 | 0.090 |
Why?
| | Double-Blind Method | 4 | 2014 | 1664 | 0.090 |
Why?
| | Antiviral Agents | 1 | 2015 | 651 | 0.090 |
Why?
| | Colitis, Ulcerative | 1 | 2011 | 106 | 0.090 |
Why?
| | Viremia | 1 | 2010 | 122 | 0.090 |
Why?
| | Diagnosis, Differential | 3 | 2015 | 1359 | 0.090 |
Why?
| | Caspase 3 | 1 | 2010 | 237 | 0.090 |
Why?
| | Phenotype | 5 | 2019 | 2859 | 0.080 |
Why?
| | Immunoglobulins | 2 | 2023 | 148 | 0.080 |
Why?
| | Cell Transplantation | 1 | 2009 | 37 | 0.080 |
Why?
| | Odds Ratio | 3 | 2019 | 968 | 0.080 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 1 | 2017 | 964 | 0.080 |
Why?
| | Gastrostomy | 1 | 2010 | 89 | 0.080 |
Why?
| | Paracrine Communication | 1 | 2009 | 56 | 0.080 |
Why?
| | Neoplastic Stem Cells | 1 | 2012 | 330 | 0.080 |
Why?
| | Radiotherapy, Conformal | 1 | 2009 | 68 | 0.080 |
Why?
| | Age Factors | 3 | 2019 | 2911 | 0.080 |
Why?
| | Receptors, Antigen, T-Cell | 2 | 2024 | 631 | 0.080 |
Why?
| | Hyalin | 1 | 2008 | 5 | 0.080 |
Why?
| | Leukocyte Reduction Procedures | 1 | 2008 | 25 | 0.080 |
Why?
| | Prosthesis Implantation | 1 | 2010 | 139 | 0.080 |
Why?
| | Gene Expression Regulation, Neoplastic | 3 | 2022 | 1143 | 0.080 |
Why?
| | Dermatofibrosarcoma | 1 | 2008 | 9 | 0.080 |
Why?
| | ras Proteins | 1 | 2009 | 137 | 0.080 |
Why?
| | Neoplastic Cells, Circulating | 1 | 2008 | 59 | 0.080 |
Why?
| | Chemokine CXCL12 | 1 | 2008 | 75 | 0.080 |
Why?
| | Kaplan-Meier Estimate | 3 | 2019 | 816 | 0.080 |
Why?
| | Length of Stay | 3 | 2019 | 960 | 0.080 |
Why?
| | Interleukin-4 | 2 | 2007 | 212 | 0.080 |
Why?
| | Chemotaxis, Leukocyte | 1 | 2008 | 130 | 0.080 |
Why?
| | DNA Mutational Analysis | 3 | 2016 | 378 | 0.080 |
Why?
| | Programmed Cell Death 1 Receptor | 2 | 2023 | 193 | 0.080 |
Why?
| | High-Throughput Nucleotide Sequencing | 2 | 2024 | 446 | 0.080 |
Why?
| | Logistic Models | 4 | 2016 | 1863 | 0.080 |
Why?
| | Kidney Failure, Chronic | 1 | 2013 | 491 | 0.070 |
Why?
| | Critical Care | 1 | 2012 | 480 | 0.070 |
Why?
| | Anticoagulants | 1 | 2012 | 549 | 0.070 |
Why?
| | Interleukin-3 Receptor alpha Subunit | 1 | 2007 | 16 | 0.070 |
Why?
| | Deoxycytidine | 1 | 2008 | 140 | 0.070 |
Why?
| | Interleukin-2 Receptor alpha Subunit | 1 | 2007 | 66 | 0.070 |
Why?
| | Interleukin-6 | 4 | 1999 | 677 | 0.070 |
Why?
| | Phylogeny | 2 | 2024 | 806 | 0.070 |
Why?
| | Career Mobility | 1 | 2007 | 64 | 0.070 |
Why?
| | Interleukin-1beta | 2 | 2019 | 370 | 0.070 |
Why?
| | Mice, Knockout | 3 | 2022 | 2608 | 0.070 |
Why?
| | alpha-Defensins | 1 | 2006 | 11 | 0.070 |
Why?
| | DNA, Bacterial | 2 | 2019 | 309 | 0.070 |
Why?
| | Blood Transfusion | 1 | 2009 | 277 | 0.070 |
Why?
| | Watchful Waiting | 2 | 2018 | 57 | 0.070 |
Why?
| | Computational Biology | 2 | 2024 | 540 | 0.070 |
Why?
| | Neoplasms, Unknown Primary | 1 | 2006 | 12 | 0.070 |
Why?
| | History, 20th Century | 1 | 2007 | 275 | 0.070 |
Why?
| | Laparotomy | 1 | 2007 | 97 | 0.070 |
Why?
| | Immunohistochemistry | 5 | 2008 | 1644 | 0.070 |
Why?
| | Collagen | 1 | 2008 | 415 | 0.070 |
Why?
| | Intestine, Small | 1 | 2007 | 125 | 0.070 |
Why?
| | Interleukin-17 | 2 | 2019 | 106 | 0.070 |
Why?
| | Lipopolysaccharides | 1 | 2009 | 832 | 0.070 |
Why?
| | Lymphocyte Culture Test, Mixed | 1 | 2005 | 43 | 0.070 |
Why?
| | Mice, Inbred BALB C | 5 | 2003 | 1169 | 0.070 |
Why?
| | Obesity, Morbid | 1 | 2008 | 199 | 0.060 |
Why?
| | Immunity, Cellular | 1 | 2007 | 263 | 0.060 |
Why?
| | Proto-Oncogene Proteins | 1 | 2009 | 609 | 0.060 |
Why?
| | Cell Line, Tumor | 3 | 2018 | 2749 | 0.060 |
Why?
| | Cell Division | 2 | 2005 | 760 | 0.060 |
Why?
| | Culture Media | 1 | 2005 | 156 | 0.060 |
Why?
| | Endoscopic Ultrasound-Guided Fine Needle Aspiration | 2 | 2016 | 52 | 0.060 |
Why?
| | Thoracic Neoplasms | 1 | 2005 | 33 | 0.060 |
Why?
| | Quality Improvement | 1 | 2012 | 958 | 0.060 |
Why?
| | Faculty, Medical | 1 | 2007 | 234 | 0.060 |
Why?
| | Mice, Inbred Strains | 1 | 2005 | 399 | 0.060 |
Why?
| | RNA, Messenger | 2 | 2005 | 2581 | 0.060 |
Why?
| | Fellowships and Scholarships | 1 | 2007 | 241 | 0.060 |
Why?
| | Nitric Oxide | 2 | 2001 | 833 | 0.060 |
Why?
| | Leadership | 1 | 2007 | 303 | 0.060 |
Why?
| | Surgical Procedures, Operative | 1 | 2006 | 210 | 0.060 |
Why?
| | Carcinoma | 1 | 2006 | 200 | 0.060 |
Why?
| | Pregnancy Complications, Neoplastic | 1 | 2004 | 50 | 0.060 |
Why?
| | Monitoring, Immunologic | 1 | 2023 | 22 | 0.060 |
Why?
| | New York | 1 | 2023 | 110 | 0.060 |
Why?
| | Neoplasm Invasiveness | 2 | 2018 | 445 | 0.060 |
Why?
| | Receptors, Lysophosphatidic Acid | 1 | 2023 | 29 | 0.060 |
Why?
| | Multilocus Sequence Typing | 1 | 2022 | 12 | 0.050 |
Why?
| | Toll-Like Receptor 4 | 1 | 2005 | 288 | 0.050 |
Why?
| | Child | 4 | 2019 | 18537 | 0.050 |
Why?
| | Chemoradiotherapy, Adjuvant | 1 | 2023 | 40 | 0.050 |
Why?
| | Antigens, CD1 | 2 | 2015 | 57 | 0.050 |
Why?
| | Receptors, KIR | 1 | 2023 | 92 | 0.050 |
Why?
| | Axilla | 2 | 2017 | 39 | 0.050 |
Why?
| | Body Weight | 4 | 2003 | 868 | 0.050 |
Why?
| | Hypoglycemia | 1 | 2007 | 387 | 0.050 |
Why?
| | Thymus Gland | 1 | 2023 | 298 | 0.050 |
Why?
| | Uveal Neoplasms | 1 | 2021 | 8 | 0.050 |
Why?
| | Veterans | 1 | 2013 | 1232 | 0.050 |
Why?
| | Cell- and Tissue-Based Therapy | 1 | 2022 | 57 | 0.050 |
Why?
| | Dietary Proteins | 1 | 2003 | 126 | 0.050 |
Why?
| | Receptors, Antigen, T-Cell, alpha-beta | 1 | 2023 | 310 | 0.050 |
Why?
| | Corticosterone | 1 | 2003 | 248 | 0.050 |
Why?
| | NF-kappa B | 1 | 2005 | 639 | 0.050 |
Why?
| | Leptin | 1 | 2003 | 211 | 0.050 |
Why?
| | Propionates | 1 | 2021 | 33 | 0.050 |
Why?
| | Remission, Spontaneous | 1 | 2021 | 37 | 0.050 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 2 | 2019 | 242 | 0.050 |
Why?
| | Mediastinoscopy | 1 | 2021 | 3 | 0.050 |
Why?
| | Precision Medicine | 2 | 2016 | 356 | 0.050 |
Why?
| | Body Mass Index | 1 | 2008 | 1974 | 0.050 |
Why?
| | Glycoproteins | 2 | 2015 | 311 | 0.050 |
Why?
| | Ephrin-B2 | 1 | 2021 | 35 | 0.050 |
Why?
| | Neoplasm Transplantation | 3 | 2012 | 235 | 0.050 |
Why?
| | Positron-Emission Tomography | 3 | 2008 | 285 | 0.050 |
Why?
| | Acetates | 1 | 2021 | 96 | 0.050 |
Why?
| | Cholangiography | 1 | 2000 | 16 | 0.050 |
Why?
| | Acetylation | 1 | 2021 | 212 | 0.050 |
Why?
| | Fibroblasts | 1 | 2005 | 838 | 0.050 |
Why?
| | Thoracoscopy | 1 | 2020 | 53 | 0.050 |
Why?
| | Tissue Banks | 1 | 2020 | 18 | 0.050 |
Why?
| | Immunotherapy, Adoptive | 1 | 2022 | 194 | 0.040 |
Why?
| | Esophageal Mucosa | 1 | 2020 | 17 | 0.040 |
Why?
| | Statistics, Nonparametric | 2 | 2012 | 390 | 0.040 |
Why?
| | Genome, Bacterial | 1 | 2021 | 106 | 0.040 |
Why?
| | Coloring Agents | 2 | 2012 | 71 | 0.040 |
Why?
| | Regression Analysis | 2 | 2019 | 960 | 0.040 |
Why?
| | Interleukin-12 Subunit p35 | 1 | 2019 | 3 | 0.040 |
Why?
| | Imaging, Three-Dimensional | 2 | 2016 | 495 | 0.040 |
Why?
| | Image-Guided Biopsy | 1 | 2019 | 33 | 0.040 |
Why?
| | Margins of Excision | 1 | 2019 | 29 | 0.040 |
Why?
| | Eating | 2 | 2003 | 349 | 0.040 |
Why?
| | Paclitaxel | 2 | 2012 | 192 | 0.040 |
Why?
| | Radiography | 2 | 2016 | 826 | 0.040 |
Why?
| | Analysis of Variance | 2 | 2012 | 1227 | 0.040 |
Why?
| | Tight Junctions | 1 | 2019 | 71 | 0.040 |
Why?
| | Organ Size | 2 | 2016 | 434 | 0.040 |
Why?
| | Case-Control Studies | 2 | 2017 | 3054 | 0.040 |
Why?
| | Patient Satisfaction | 1 | 2022 | 585 | 0.040 |
Why?
| | Preoperative Period | 1 | 2019 | 103 | 0.040 |
Why?
| | Montana | 1 | 2018 | 16 | 0.040 |
Why?
| | United States Environmental Protection Agency | 1 | 2018 | 23 | 0.040 |
Why?
| | Mitogens | 1 | 1998 | 58 | 0.040 |
Why?
| | Keratins | 2 | 2010 | 176 | 0.040 |
Why?
| | Sexual and Gender Minorities | 1 | 2021 | 138 | 0.040 |
Why?
| | Cachexia | 1 | 1999 | 52 | 0.040 |
Why?
| | Interleukin-18 | 1 | 2019 | 222 | 0.040 |
Why?
| | Robotic Surgical Procedures | 1 | 2019 | 88 | 0.040 |
Why?
| | Tumor Suppressor Protein p53 | 1 | 2022 | 448 | 0.040 |
Why?
| | Colony Count, Microbial | 1 | 2018 | 113 | 0.040 |
Why?
| | Receptor, ErbB-2 | 1 | 2020 | 302 | 0.040 |
Why?
| | Sensitivity and Specificity | 2 | 2015 | 1725 | 0.040 |
Why?
| | Pedigree | 1 | 2019 | 474 | 0.040 |
Why?
| | Qualitative Research | 1 | 2022 | 966 | 0.040 |
Why?
| | Evidence-Based Medicine | 1 | 2002 | 685 | 0.040 |
Why?
| | Perioperative Period | 1 | 2017 | 49 | 0.040 |
Why?
| | Principal Component Analysis | 1 | 2018 | 178 | 0.040 |
Why?
| | Jejunostomy | 1 | 1997 | 11 | 0.040 |
Why?
| | Femoral Fractures | 1 | 1998 | 67 | 0.040 |
Why?
| | Rosaniline Dyes | 2 | 2007 | 10 | 0.040 |
Why?
| | Operative Time | 1 | 2017 | 109 | 0.040 |
Why?
| | Dinoprostone | 1 | 1998 | 188 | 0.040 |
Why?
| | Candidiasis | 1 | 1997 | 58 | 0.040 |
Why?
| | Ki-67 Antigen | 1 | 2017 | 104 | 0.040 |
Why?
| | Antigen-Presenting Cells | 1 | 2017 | 152 | 0.040 |
Why?
| | Occipital Bone | 1 | 2017 | 18 | 0.040 |
Why?
| | Parotid Gland | 1 | 2017 | 26 | 0.040 |
Why?
| | DNA, Ribosomal | 1 | 2017 | 80 | 0.040 |
Why?
| | Liver Circulation | 1 | 2016 | 21 | 0.040 |
Why?
| | Infection Control | 1 | 1998 | 137 | 0.040 |
Why?
| | Ultrasonography, Doppler, Color | 1 | 2016 | 34 | 0.040 |
Why?
| | Quality of Health Care | 2 | 2012 | 577 | 0.040 |
Why?
| | ErbB Receptors | 1 | 2020 | 557 | 0.030 |
Why?
| | Radiotherapy Dosage | 2 | 2008 | 246 | 0.030 |
Why?
| | Neck | 1 | 2017 | 85 | 0.030 |
Why?
| | Histones | 1 | 2021 | 539 | 0.030 |
Why?
| | Costs and Cost Analysis | 1 | 1997 | 200 | 0.030 |
Why?
| | Adaptor Proteins, Signal Transducing | 1 | 2019 | 377 | 0.030 |
Why?
| | Protein Binding | 1 | 2022 | 1918 | 0.030 |
Why?
| | Superinfection | 1 | 2016 | 5 | 0.030 |
Why?
| | Sequence Analysis, RNA | 1 | 2018 | 390 | 0.030 |
Why?
| | Hydrogen Peroxide | 1 | 1998 | 286 | 0.030 |
Why?
| | Receptors, CXCR5 | 1 | 2016 | 11 | 0.030 |
Why?
| | Radiotherapy, Adjuvant | 2 | 2008 | 182 | 0.030 |
Why?
| | Models, Anatomic | 1 | 2016 | 92 | 0.030 |
Why?
| | Feasibility Studies | 2 | 2010 | 750 | 0.030 |
Why?
| | Cross-Sectional Studies | 2 | 2017 | 4447 | 0.030 |
Why?
| | Host Specificity | 1 | 2016 | 23 | 0.030 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 2 | 2008 | 935 | 0.030 |
Why?
| | Incidental Findings | 1 | 2016 | 77 | 0.030 |
Why?
| | Autoimmune Diseases | 1 | 2019 | 396 | 0.030 |
Why?
| | Primary Cell Culture | 1 | 2016 | 148 | 0.030 |
Why?
| | Asymptomatic Diseases | 1 | 2016 | 77 | 0.030 |
Why?
| | Cluster Analysis | 1 | 2017 | 466 | 0.030 |
Why?
| | Pandemics | 1 | 2023 | 1337 | 0.030 |
Why?
| | Prevotella | 1 | 2015 | 12 | 0.030 |
Why?
| | Macaca mulatta | 1 | 2015 | 132 | 0.030 |
Why?
| | Virion | 1 | 2015 | 74 | 0.030 |
Why?
| | DNA Copy Number Variations | 1 | 2016 | 157 | 0.030 |
Why?
| | HEK293 Cells | 1 | 2017 | 603 | 0.030 |
Why?
| | Endoscopy, Digestive System | 1 | 2016 | 109 | 0.030 |
Why?
| | Sexual Behavior | 1 | 2019 | 440 | 0.030 |
Why?
| | Cell Cycle | 1 | 2017 | 546 | 0.030 |
Why?
| | CD40 Antigens | 1 | 2015 | 80 | 0.030 |
Why?
| | Protein-Tyrosine Kinases | 1 | 1998 | 394 | 0.030 |
Why?
| | Magnetic Resonance Imaging | 2 | 2008 | 3072 | 0.030 |
Why?
| | Nausea | 1 | 2014 | 103 | 0.030 |
Why?
| | Mitotic Index | 1 | 2014 | 26 | 0.030 |
Why?
| | Glucocorticoids | 1 | 1999 | 551 | 0.030 |
Why?
| | Patient Readmission | 1 | 2019 | 609 | 0.030 |
Why?
| | Vomiting | 1 | 2014 | 125 | 0.030 |
Why?
| | Sequence Analysis, DNA | 1 | 2017 | 737 | 0.030 |
Why?
| | Cattle | 1 | 2016 | 935 | 0.030 |
Why?
| | Colitis | 1 | 2016 | 226 | 0.030 |
Why?
| | Inflammation | 2 | 2019 | 2502 | 0.030 |
Why?
| | ROC Curve | 1 | 2015 | 451 | 0.030 |
Why?
| | Clinical Decision-Making | 1 | 2016 | 273 | 0.030 |
Why?
| | Phosphorylation | 1 | 1998 | 1562 | 0.030 |
Why?
| | Hemorrhage | 1 | 1998 | 617 | 0.030 |
Why?
| | Reproducibility of Results | 1 | 2021 | 2807 | 0.030 |
Why?
| | CD4 Lymphocyte Count | 1 | 2014 | 257 | 0.030 |
Why?
| | Caspase 1 | 1 | 2014 | 141 | 0.030 |
Why?
| | Cell Lineage | 1 | 2015 | 310 | 0.030 |
Why?
| | Autoantigens | 1 | 2016 | 399 | 0.030 |
Why?
| | Genes, Immunoglobulin Heavy Chain | 1 | 2013 | 10 | 0.030 |
Why?
| | Practice Guidelines as Topic | 1 | 2020 | 1405 | 0.030 |
Why?
| | Endarterectomy, Carotid | 1 | 2013 | 41 | 0.030 |
Why?
| | Immunoglobulin Heavy Chains | 1 | 2013 | 72 | 0.030 |
Why?
| | HIV Envelope Protein gp120 | 1 | 2013 | 56 | 0.030 |
Why?
| | AIDS Vaccines | 1 | 2013 | 41 | 0.030 |
Why?
| | Retinal Dehydrogenase | 1 | 2012 | 38 | 0.030 |
Why?
| | Aldehyde Oxidoreductases | 1 | 2012 | 30 | 0.030 |
Why?
| | International Agencies | 1 | 2012 | 29 | 0.030 |
Why?
| | Clinical Competence | 1 | 2019 | 924 | 0.030 |
Why?
| | Antibody Specificity | 1 | 2013 | 180 | 0.030 |
Why?
| | Homeostasis | 1 | 2016 | 577 | 0.030 |
Why?
| | Thoracotomy | 1 | 2012 | 67 | 0.030 |
Why?
| | Adoptive Transfer | 1 | 2013 | 200 | 0.030 |
Why?
| | Response Elements | 1 | 2012 | 83 | 0.030 |
Why?
| | Neoplasm Grading | 1 | 2013 | 244 | 0.030 |
Why?
| | Sequence Homology, Amino Acid | 1 | 2013 | 353 | 0.030 |
Why?
| | Aortic Aneurysm, Abdominal | 1 | 2013 | 115 | 0.030 |
Why?
| | Calcium | 1 | 1998 | 1103 | 0.030 |
Why?
| | Confidence Intervals | 1 | 2012 | 309 | 0.030 |
Why?
| | APACHE | 1 | 2012 | 60 | 0.020 |
Why?
| | Blood Coagulation Tests | 1 | 2012 | 57 | 0.020 |
Why?
| | Gene Silencing | 1 | 2012 | 176 | 0.020 |
Why?
| | Mice, SCID | 1 | 2012 | 321 | 0.020 |
Why?
| | Receptors, HIV | 1 | 2011 | 23 | 0.020 |
Why?
| | Isoenzymes | 1 | 2012 | 287 | 0.020 |
Why?
| | Species Specificity | 1 | 2013 | 553 | 0.020 |
Why?
| | Transcriptome | 1 | 2017 | 742 | 0.020 |
Why?
| | Bone Marrow | 1 | 2013 | 248 | 0.020 |
Why?
| | Drug Administration Schedule | 1 | 2013 | 724 | 0.020 |
Why?
| | Interleukin-8 | 1 | 2012 | 241 | 0.020 |
Why?
| | Cell Communication | 1 | 2013 | 280 | 0.020 |
Why?
| | Single-Blind Method | 1 | 2012 | 256 | 0.020 |
Why?
| | Models, Animal | 1 | 2013 | 350 | 0.020 |
Why?
| | CA-19-9 Antigen | 1 | 2010 | 13 | 0.020 |
Why?
| | Proportional Hazards Models | 1 | 2014 | 1088 | 0.020 |
Why?
| | Gene Expression | 1 | 2016 | 1442 | 0.020 |
Why?
| | Genes, bcl-2 | 1 | 2010 | 20 | 0.020 |
Why?
| | Factor Xa Inhibitors | 1 | 2012 | 138 | 0.020 |
Why?
| | Mice, Inbred NOD | 1 | 2012 | 562 | 0.020 |
Why?
| | Risk | 1 | 2013 | 829 | 0.020 |
Why?
| | Cell Survival | 1 | 2014 | 1024 | 0.020 |
Why?
| | Universities | 1 | 2013 | 341 | 0.020 |
Why?
| | Mice, Nude | 1 | 2012 | 639 | 0.020 |
Why?
| | Incidence | 1 | 1996 | 2336 | 0.020 |
Why?
| | RNA, Small Interfering | 1 | 2012 | 545 | 0.020 |
Why?
| | Gene Expression Profiling | 1 | 2017 | 1550 | 0.020 |
Why?
| | Patient Selection | 1 | 2014 | 655 | 0.020 |
Why?
| | Gastroscopy | 1 | 2010 | 18 | 0.020 |
Why?
| | Staining and Labeling | 1 | 2010 | 139 | 0.020 |
Why?
| | Chronic Disease | 1 | 2015 | 1598 | 0.020 |
Why?
| | Renal Dialysis | 1 | 2013 | 371 | 0.020 |
Why?
| | Polymorphism, Restriction Fragment Length | 1 | 2009 | 65 | 0.020 |
Why?
| | Keratin-20 | 1 | 2008 | 1 | 0.020 |
Why?
| | N-Acetylgalactosaminyltransferases | 1 | 2008 | 6 | 0.020 |
Why?
| | Hepatic Veno-Occlusive Disease | 1 | 2008 | 10 | 0.020 |
Why?
| | Chloroquine | 1 | 2009 | 52 | 0.020 |
Why?
| | Liver Regeneration | 1 | 2008 | 32 | 0.020 |
Why?
| | Immunoglobulin G | 1 | 2013 | 782 | 0.020 |
Why?
| | Device Removal | 1 | 2010 | 128 | 0.020 |
Why?
| | Amino Acid Sequence | 1 | 2013 | 2003 | 0.020 |
Why?
| | Dose-Response Relationship, Radiation | 1 | 2008 | 130 | 0.020 |
Why?
| | Prostheses and Implants | 1 | 2010 | 141 | 0.020 |
Why?
| | Chemokine CX3CL1 | 1 | 2008 | 22 | 0.020 |
Why?
| | Reference Standards | 1 | 2009 | 162 | 0.020 |
Why?
| | Premedication | 1 | 2008 | 36 | 0.020 |
Why?
| | Capecitabine | 1 | 2008 | 46 | 0.020 |
Why?
| | Proto-Oncogene Proteins c-met | 1 | 2008 | 67 | 0.020 |
Why?
| | Sex Factors | 1 | 2013 | 1741 | 0.020 |
Why?
| | Program Evaluation | 1 | 2012 | 841 | 0.020 |
Why?
| | Antigens, CD34 | 1 | 2008 | 97 | 0.020 |
Why?
| | Proto-Oncogene Proteins p21(ras) | 1 | 2009 | 228 | 0.020 |
Why?
| | Molecular Sequence Data | 1 | 2013 | 2796 | 0.020 |
Why?
| | Antimetabolites, Antineoplastic | 1 | 2008 | 83 | 0.020 |
Why?
| | Models, Molecular | 1 | 2013 | 1391 | 0.020 |
Why?
| | Remission Induction | 1 | 2008 | 240 | 0.020 |
Why?
| | Mice, Transgenic | 1 | 2013 | 1971 | 0.020 |
Why?
| | Acute Disease | 2 | 2003 | 917 | 0.020 |
Why?
| | Quinazolines | 1 | 2009 | 241 | 0.020 |
Why?
| | Swine | 1 | 2010 | 705 | 0.020 |
Why?
| | Body Composition | 2 | 2003 | 579 | 0.020 |
Why?
| | DNA Primers | 1 | 2008 | 514 | 0.020 |
Why?
| | Disease Models, Animal | 1 | 2016 | 3587 | 0.020 |
Why?
| | Cytotoxicity, Immunologic | 1 | 2007 | 198 | 0.020 |
Why?
| | Lewis X Antigen | 1 | 2006 | 4 | 0.020 |
Why?
| | Anti-Infective Agents | 1 | 2009 | 225 | 0.020 |
Why?
| | Polymerase Chain Reaction | 1 | 2009 | 1001 | 0.020 |
Why?
| | Epitopes, T-Lymphocyte | 1 | 2007 | 171 | 0.020 |
Why?
| | Whole Body Imaging | 1 | 2006 | 25 | 0.020 |
Why?
| | Gene Expression Regulation | 1 | 2015 | 2365 | 0.020 |
Why?
| | Infant | 1 | 2019 | 7992 | 0.020 |
Why?
| | Fluorescent Dyes | 1 | 2007 | 303 | 0.020 |
Why?
| | Neoplasm Proteins | 1 | 2008 | 388 | 0.020 |
Why?
| | Patient Discharge | 1 | 2011 | 770 | 0.020 |
Why?
| | Radiotherapy | 1 | 2006 | 177 | 0.020 |
Why?
| | Microscopy, Fluorescence | 1 | 2006 | 402 | 0.020 |
Why?
| | Base Sequence | 1 | 2008 | 2121 | 0.010 |
Why?
| | Pregnancy Trimester, Third | 1 | 2004 | 77 | 0.010 |
Why?
| | Colorado | 1 | 2013 | 4122 | 0.010 |
Why?
| | Specific Pathogen-Free Organisms | 1 | 2003 | 60 | 0.010 |
Why?
| | Appetite Regulation | 1 | 2003 | 26 | 0.010 |
Why?
| | Adrenalectomy | 1 | 2003 | 80 | 0.010 |
Why?
| | Drug Implants | 1 | 2003 | 71 | 0.010 |
Why?
| | Random Allocation | 1 | 2003 | 337 | 0.010 |
Why?
| | Cycloheximide | 1 | 2001 | 56 | 0.010 |
Why?
| | Dactinomycin | 1 | 2001 | 25 | 0.010 |
Why?
| | Peritoneum | 1 | 2001 | 36 | 0.010 |
Why?
| | Mice, Inbred C3H | 1 | 2001 | 244 | 0.010 |
Why?
| | Coculture Techniques | 1 | 2001 | 204 | 0.010 |
Why?
| | Hormone Antagonists | 1 | 1999 | 38 | 0.010 |
Why?
| | Mifepristone | 1 | 1999 | 65 | 0.010 |
Why?
| | Mice, Inbred DBA | 1 | 1999 | 173 | 0.010 |
Why?
| | Candida albicans | 1 | 1997 | 55 | 0.010 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2001 | 1871 | 0.010 |
Why?
| | Obesity | 1 | 2008 | 2523 | 0.010 |
Why?
| | RNA | 1 | 2001 | 820 | 0.010 |
Why?
| | Injury Severity Score | 1 | 1996 | 460 | 0.010 |
Why?
| | Pregnancy | 1 | 2004 | 5555 | 0.010 |
Why?
| | Kidney | 1 | 1997 | 1210 | 0.010 |
Why?
|
|
McCarter's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|